## IN THIS ISSUE
Highlighted research articles .................. 477

## NEWS IN BRIEF
Important news stories affecting the community .......... 480

## NEWS IN DEPTH
Q&A: Antoni Ribas on Progress in Melanoma ............ 483
Cancer Immunotherapy: Make Way for CAR NK .......... 484

## RESEARCH WATCH
Selected highlights of recent articles of exceptional significance from the cancer literature ........... 485

## ONLINE
For more News and Research Watch, visit Cancer Discovery online at http://cancerdiscovery.aacrjournals.org/CDNews.

## VIEWS
In The Spotlight

**Letting the GENIE Out of Its Bottle: Examining the Potential of Real-World Clinicogenomic Data .................. 490**
E. Castellanos and S.S. Baxi
See article, p. 526

**Not So FAST: Tumor Cells Resisting Death Drive CAR T-cell Dysfunction ............ 492**
M.R. Green and S.S. Neelapu
See article, p. 552

**Deconstructing Pancreatic Adenocarcinoma by Targeting the Conductor, MYC ............ 495**
I.A. English and R.C. Sears
See article, p. 588

## MINI REVIEW
Advances in Targeting RET-Dependent Cancers ..... 498
V. Subbiah and G.J. Cote

## REVIEW
Advances in the Treatment of Acute Myeloid Leukemia: New Drugs and New Challenges ............. 506
N.J. Short, M. Konopleva, T.M. Kadia, G. Barthakur, F. Ravandi, C.D. Dinardo, and N. Dave

## RESEARCH ARTICLES
Characteristics and Outcome of AKT1:E17K-Mutant Breast Cancer Defined through AACR Project GENIE, a Clinicogenomic Registry ............. 526
Précis: Data from AACR Project GENIE were used to investigate the effects of the rare AKT1:E17K mutation in ER+ breast cancer, showing the challenges and advantages of using this type of real-world evidence. See commentary, p. 490

Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia .......... 536
Précis: Compared with less differentiated acute myeloid leukemia (AML), monocytic AML is more resistant to venetoclax-based therapy, a phenomenon that may be attributable to dedifferentiation of preexisting monocytic subclones.

**E17K mutation in ER+ breast cancer, showing the challenges and advantages of using this type of real-world evidence. See commentary, p. 490**

**Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia .......... 536**
Précis: Compared with less differentiated acute myeloid leukemia (AML), monocytic AML is more resistant to venetoclax-based therapy, a phenomenon that may be attributable to dedifferentiation of preexisting monocytic subclones.

**Monocytic Subclones Confer Resistance to Venetoclax-Based Therapy in Patients with Acute Myeloid Leukemia .......... 536**
Précis: Compared with less differentiated acute myeloid leukemia (AML), monocytic AML is more resistant to venetoclax-based therapy, a phenomenon that may be attributable to dedifferentiation of preexisting monocytic subclones.
Impaired Death Receptor Signaling in Leukemia Causes Antigen-Independent Resistance by Inducing CAR T-cell Dysfunction


Précis: Response to CD19-directed CAR T cells in acute lymphoblastic leukemia was dependent on death receptor signaling, and exposure to ALL cells with impaired death receptor signaling caused CAR T cells to adopt an exhausted-like phenotype.

See commentary, p. 492

Relapse-Fated Latent Diagnosis
Subclones in Acute B Lineage Leukemia Are Drug Tolerant and Possess Distinct Metabolic Programs


Précis: Minor subclones that are present at the time of diagnosis in B-progenitor acute lymphoblastic leukemia can cause relapse and exhibit distinct traits, including chemotherapy resistance, prior to treatment.

See commentary, p. 495

MYC Instructs and Maintains Pancreatic Adenocarcinoma Phenotype


Précis: In a mouse model of mutant Kras–driven pancreatic ductal adenocarcinoma (PDAC), Myc activation was required for progression to PDAC, whereas Myc deactivation caused rapid regression of even established PDACs.

See commentary, p. 495

Oncogenic KRAS-Driven Metabolic Reprogramming in Pancreatic Cancer Cells Utilizes Cytokines from the Tumor Microenvironment


Précis: In models of mutant Kras–driven pancreatic cancer, Th2 cells in the tumor microenvironment produced the cytokines IL4 and IL13, which promoted metabolic reprogramming and tumorigenesis.